ANI Pharmaceuticals (NASDAQ:ANIP) Receives “Buy” Rating from Guggenheim

Guggenheim restated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report issued on Friday morning,Benzinga reports. They currently have a $86.00 price objective on the specialty pharmaceutical company’s stock.

Several other brokerages have also issued reports on ANIP. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price objective on the stock. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Finally, Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $79.75.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $68.12 on Friday. The company’s 50-day moving average is $62.34 and its two-hundred day moving average is $59.07. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.00. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -123.85 and a beta of 0.49.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,200 shares of company stock valued at $191,776. 12.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Exchange Traded Concepts LLC grew its position in ANI Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after purchasing an additional 310 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock worth $582,000 after buying an additional 364 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after acquiring an additional 412 shares during the last quarter. Natixis Advisors LLC lifted its position in ANI Pharmaceuticals by 2.3% during the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock worth $1,028,000 after acquiring an additional 417 shares during the period. Finally, US Bancorp DE grew its stake in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.